文献速递头颈外科

美国健康成年人群口腔人乳头瘤病毒患病率及基因分型

Oral Human Papillomavirus Prevalence and Genotyping Among a Healthy Adult Population in the US.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2023-01-01

PROGRESS是一项横断面观察研究,2021年11月至2022年3月在美国43家牙科诊所纳入3196名18至60岁成年人,检测口腔HPV DNA及基因型。任何HPV基因型患病率为6.6%,高危型为2.0%,HPV-16为0.7%,9价疫苗型别为1.5%。男性及51至60岁男性患病率最高,高危型感染与男性、51至60岁、终身男性性伴侣数≥26及终身女性口交伴侣数6至25相关。

要点

  • 口腔任何HPV基因型患病率为6.6%,高危型为2.0%,HPV-16为0.7%。
  • 男性口腔HPV患病率高于女性,51至60岁男性最高。
  • 高危型口腔感染与男性、51至60岁及特定性行为因素相关。

核心结论

  • 在这项横断面研究中,口腔HPV负担在年龄较大的男性中最高,该人群可能具有更高的口咽癌风险。
  • 除男性性别和年龄较大外,高危型口腔HPV感染还与性行为相关,包括男性性伴侣数和女性口交伴侣数增加。

研究设计与样本

  • PROGRESS(口腔HPV感染患病率全球评估)是一项横断面观察研究,于2021年11月至2022年3月在美国21个州的43家牙科诊所(24个城市、13个城市集群、6个农村地点)开展。
  • 纳入18至60岁因常规牙科检查就诊的参与者,牙科诊所采用靶向抽样以招募男女及各年龄组分布均衡的参与者。
  • 参与者提供口腔漱口液标本用于HPV DNA检测及基因分型,并完成行为问卷,牙医报告口腔健康状况。
  • HPV DNA检测及基因分型采用SPF10/DEIA/LiPA25系统在中心实验室进行。
  • 共纳入3196名参与者,平均(SD)年龄为39.6(12.1)岁,55.5%为女性。

主要发现

  • 任何HPV基因型口腔患病率为6.6%(95%CI,5.7%-7.4%),高危型为2.0%(95%CI,1.5%-2.5%),HPV-16为0.7%(95%CI,0.4%-1.0%),9价HPV疫苗型别为1.5%(95%CI,1.1%-1.9%)。
  • 在HPV阳性参与者中,HPV-16是最常见的基因型,男性中占12.4%,女性中占8.6%。
  • 男性口腔HPV患病率高于女性;51至60岁男性中,任何HPV、高危型HPV和HPV-16患病率分别为16.8%、6.8%和2.1%。
  • 与高危型口腔感染相关的因素包括男性(AOR,3.1;95%CI,1.2-8.5)、51至60岁(AOR,3.3;95%CI,1.5-7.3)、终身男性性伴侣数≥26(AOR,6.5;95%CI,2.3-18.7)及终身女性口交伴侣数6至25(AOR,3.4;95%CI,1.3-8.7)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the US, oropharyngeal cancer, predominantly caused by high-risk (HR) human papillomavirus (HPV) infection, is the most frequent HPV-associated cancer, surpassing cervical cancer. However, little is known about oral HPV prevalence and genotype distribution in the general population. OBJECTIVE: To assess oral HPV prevalence and factors associated with HR and low-risk infection in a general US population. DESIGN, SETTING, AND PARTICIPANTS: PROGRESS (Prevalence of Oral HPV Infection, a Global Assessment) was a cross-sectional observational study conducted between November 2021 and March 2022 in 43 dental offices in the US (24 urban, 13 urban cluster, and 6 rural sites), spanning 21 states. Eligible participants were aged 18 to 60 years, visiting dental clinics for routine dental examination. Dental clinics used targeted sampling to recruit equal distributions of men and women and across age groups. EXPOSURE: Participants provided an oral gargle specimen for HPV DNA and genotyping and completed behavioral questionnaires, and dentists reported oral health status. Detection of HPV DNA and genotyping was performed using the SPF10/DEIA/LiPA25 system at a central laboratory. MAIN OUTCOME: Oral HPV prevalence. RESULTS: Of the 3196 participants enrolled, mean (SD) age was 39.6 (12.1) years, and 55.5% were women. Oral HPV prevalence was 6.6% (95% CI, 5.7%-7.4%) for any HPV genotype, and 2.0% (95% CI, 1.5%-2.5%), 0.7% (95% CI, 0.4%-1.0%), and 1.5% (95% CI, 1.1%-1.9%) for HR, HPV-16, and 9-valent-HPV vaccine types, respectively. Among HPV-positive participants, HPV-16 was the most prevalent genotype (12.4% among men and 8.6% among women). Prevalence of HPV was higher in men than women and highest among men aged 51 to 60 years (16.8%, 6.8%, and 2.1% for any HPV, HR HPV, and HPV-16, respectively). Factors associated with HR oral infection included being male (adjusted odds ratio [AOR], 3.1; 95% CI, 1.2-8.5), being aged 51 to 60 years (AOR, 3.3; 95% CI, 1.5-7.3), having 26 or more lifetime male sex partners (AOR, 6.5; 95% CI, 2.3-18.7), and having 6 to 25 lifetime female oral sex partners (AOR, 3.4; 95% CI, 1.3-8.7). CONCLUSIONS AND RELEVANCE: In this cross-sectional study, oral HPV burden was highest among older men who may be at higher risk of developing oropharyngeal cancer. In addition to male sex and older age, HR oral HPV infection was also associated with sexual behaviors, including increasing number of male sex partners and female oral sex partners.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Giuliano AR, Felsher M, Waterboer T, et al. Oral Human Papillomavirus Prevalence and Genotyping Among a Healthy Adult Population in the US. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 37535349. doi:10.1001/jamaoto.2023.1573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。